Shen 2020.

Methods	Study design: Randomised clinical trial Study duration: January 2015 to February 2017 Duration of follow‐up: 2 years Setting: Hospital
Participants	Number of participants: 67 Inclusion criteria: Diagnosed as HCC Age (mean ± SD): TACE + RFA: 59.62 ± 5.05 years; TACE alone: 59.63 ± 5.02 years Male (n/total): TACE + MWA: 21/33; TACE alone: 24/34
Interventions	TACE + RFA group (n = 33) Control group (n = 34)
Outcomes	Sleep: measured by a score system for sleeping Survival rates and recurrence: measured at 2 years after treatment
Notes	Country of study: China Source of funding: None There was insufficient information available to satisfactorily determine the method of randomisation and the study data could not be verified. We have attempted to contact the study authors for more information, but so far, we have not been successful in doing this.